New reforms in New South Wales have enabled approximately 10,000 patients to access ADHD treatment, highlighting a significant shift in prescribing access and policy for stimulant medications.

A JAMA study indicates the 988 suicide and crisis lifeline is associated with a significant reduction in suicide mortality among adolescents and young adults, supporting sustained funding for crisis intervention services.

Weight gain occurring within the first 12 weeks of antipsychotic treatment is identified as the primary predictor of long-term obesity, highlighting a critical window for early intervention in psychosis care.

This study identifies distinct patterns of self-awareness regarding gesture behavior in schizophrenia versus depression, suggesting that integrating self-report measures with objective assessments is critical for tailoring social communication interventions.

The article outlines the paradigm shift from viewing insomnia as secondary to other conditions to recognizing it as an independent disorder requiring specific treatment, noting that addressing sleep can improve comorbid psychiatric and physical conditions.

This article evaluates the clinical efficacy of adding lithium to valproate for managing agitation in patients with schizophrenia, offering evidence-based guidance for combination pharmacotherapy.

First responders with PTSD are participating in a clinical trial evaluating psilocybin as a potential treatment for trauma-related symptoms.

Concurrent use of SSRIs with antipsychotics may increase cardiac risk, necessitating careful cardiovascular monitoring in psychiatric prescribing.

Valproic acid co-administration significantly reduces norclozapine plasma levels by approximately 49% and lowers absolute neutrophil counts, necessitating pharmacogenomic consideration of UGT polymorphisms to optimize clozapine efficacy and safety in schizophrenia.

This author correction clarifies typographical errors in a study describing a novel µ-opioid receptor superagonist with reduced adverse effects, relevant to the development of next-generation analgesics for substance use disorders.

A new survey estimates 8 million Americans used psilocybin in 2024, highlighting a significant rise in the use of this psychedelic substance with potential implications for future psychiatric treatment and safety monitoring.

This study characterizes purchasing patterns of low-alcohol beverages in Great Britain, identifying distinct consumer subgroups with varying alcohol risk profiles to inform public health strategies for Substance Use.

A large-scale survey estimates that 2.8% of the U.S. population used psilocybin in the past year, providing critical epidemiological data for clinicians monitoring emerging psychedelic use patterns.

This systematic review identifies single-item patient-reported outcome measures for substance use treatment that offer valid, reliable alternatives to lengthy assessments for monitoring craving, treatment readiness, and self-efficacy.

A new study indicates that a common antidepressant may help reduce methamphetamine use, suggesting potential repurposing for substance use disorder treatment.

This study identifies childhood trauma-specific functional connectome disruptions in adolescent MDD and demonstrates that baseline connectivity patterns can predict antidepressant response with 82% accuracy, supporting the use of neuroimaging biomarkers for precision treatment.

This fMRI study demonstrates that augmenting extinction training with counterconditioning strengthens neural safety representations in PTSD, offering a potential mechanism to enhance exposure therapy efficacy.

This fMRI study identifies distinct neural response patterns to reward uncertainty in adolescents with mood and anxiety symptoms, linking blunted striatal responses during expectancy to anxiety severity and default network activation to anhedonia.

Identification of a shared neural pathway between the motor and insular cortex in Tourette's and OCD provides mechanistic insight for future pharmacological targeting but does not currently alter prescribing practices.

This case report highlights reversible cerebral vasoconstriction syndrome (RCVS) as a rare but serious adverse event associated with sertraline reinitiation, necessitating heightened clinical vigilance for thunderclap headaches in patients using SSRIs.

A randomized usability trial evaluates a nurse-driven clinical decision support system to improve documentation and assessment of opioid withdrawal severity in Opioid Use Disorder.

This article describes a clinical trial evaluating VR-based relaxation to manage anxiety specifically associated with electroconvulsive therapy (ECT).

This article describes a clinical trial evaluating an AI-based rehabilitation device combined with standard treatment for anxiety disorders, representing a digital health intervention rather than direct pharmacological news.

This article describes a clinical trial evaluating VR-based relaxation to manage anxiety specifically associated with electroconvulsive therapy (ECT).

This article discusses the potential of functional connectivity neurofeedback as a precision treatment modality for psychiatric symptoms, representing an emerging non-pharmacological intervention.

A large-scale Swedish and Finnish cohort study identifies specific antipsychotic and mood stabilizer combinations that significantly reduce relapse risk compared to lithium monotherapy in bipolar disorder patients, offering evidence-based alternatives for those with inadequate response or intolerance.

This article is an obituary for William H. Morse, a founding figure in behavioral pharmacology whose work on drug effects on operant behavior laid the groundwork for modern psychiatric psychopharmacology.

This review reframes contemporary psychosurgery as circuit-based medicine using connectomics to guide neuromodulation and ablation for treatment-resistant psychiatric conditions, emphasizing integration with pharmacological strategies.

A novel discovery linking Tourette's tics to an emotion-linked brain circuit suggests potential new therapeutic targets beyond traditional motor-focused approaches.

This study identifies IL-15 receptor alpha deficiency as a mechanism for depressive-like behaviors through enhanced microglial synapse pruning, offering a novel target for future pharmacological intervention.

This preclinical study indicates that NMDA receptor antagonism requires intact serotonin and noradrenaline signaling to produce antidepressant effects, suggesting potential limitations for ketamine-based therapies in patients with severe monoaminergic deficits.

This study identifies a shared neural network targeted by diverse antidepressant therapies, offering mechanistic insights that may inform future drug development and treatment selection.